%{search_type} search results

5,158 catalog results

RSS feed for this result
xv, 400 pages : illustrations ; 25 cm
  • Thorazine: Awake!
  • Lithium: a salted stone
  • Early antidepressants: the three-ringed molecule and the psychic energizer
  • SSRIs: the birth of Prozac
  • Placebos: the dancing disease
  • Psilocybin (magic mushrooms): God's flesh
  • MDMA (Ecstasy): the marriage medicine
  • PKMzeta/ZIP (memory drugs): the spotless mind
  • Deep brain stimulation: Who holds the clicker?
  • Epilogue: Where we're headed.
Law Library (Crown)
xi, 239 pages : illustrations (some color) ; 22 cm
  • 1. Introduction: the West, Spain and the early circulation of penicillin.- 2. Fleming in Spain: the hero, the antimicrobial and the politics of public acclaim.- 3. Manufacturing penicillin: health, industry and gender.- 4. Smuggling: The management of scarcity and trade of penicillin as a post-war commodity.- 5. Modern Times: screening antibiotics and the factory line.- 6. A new promising drug: bacteria, antibiotics and marketing.- 7. Beyond healing: antibiotic resistance and regulatory regimes as agents in the Spanish transition to democracy.- 8. Penicillin in Spain, 1940s-1980s: Circulating health, research and gender.- 9. Final reflections.
  • (source: Nielsen Book Data)9783319697178 20180219
This book reconstructs the early circulation of penicillin in Spain, a country exhausted by civil war (1936-1939), and oppressed by Franco's dictatorship. Embedded in the post-war recovery, penicillin's voyages through time and across geographies - professional, political and social - were both material and symbolic. This powerful antimicrobial captivated the imagination of the general public, medical practice, science and industry, creating high expectations among patients, who at times experienced little or no effect. Penicillin's lack of efficacy against some microbes fueled the search for new wonder drugs and sustained a decades-long research agenda built on the post-war concept of development through scientific and technological achievements. This historical reconstruction of the social life of penicillin between the 1940s and 1980s - through the dictatorship to democratic transition - explores political, public, medical, experimental and gender issues, and the rise of antibiotic resistance.
(source: Nielsen Book Data)9783319697178 20180219
Green Library
1 online resource (535 p.) : ill. (some col.).
"Clinical research monitoring is a vital aspect of Good Clinical Practice (GCP). Its principles are straightforward: they are aimed at protecting those subjects that participate in the trial, and their goal is to provide reliable data that will contribute to the safety and efficacy of the intervention under study, i.e. to support the health of future subjects. However, the practical implementation of these major goals is complicated. Various mishaps have happened in recent history, and an extensive set of international rules and regulations have emerged. This book gives a thorough survey of the ethical and legal aspects of clinical research and provides a detailed guideline for implementing these aspects into the practice of studying investigational medicinal products in humans, in the European context. It can be used as a study aid for starting monitors, a reference guide for more experienced monitors, and anyone else involved in clinical research."--Publisher's website.
ix, 136 pages ; 22 cm.
  • 1. Identity and Taboo among Paleo Dieters2. Beleaguered Bodies: Illness and Obesity in Neoliberal Australia3. Narratives of Paleo Redemption: Agency, Resistance and the Rise of Populism in Health4. The Promise and Pitfalls of Paleo.
  • (source: Nielsen Book Data)9783319672496 20180129
This book explores the cultural and economic conditions fuelling the popularity of the polarizing Paleo diet in Australia. Based on ethnographic research in Melbourne and Sydney, Catie Gressier recounts the compelling narratives of individuals struggling with illness and weight issues. She argues that `going Paleo' provides a sense of agency and means of resistance to the neoliberal policies and practices underpinning the growing prevalence of lifestyle diseases. From its nostalgic constructions of the past, to the rise of anti-elite sentiments inherent in new forms of health populism, Gressier provides a nuanced understanding of the Paleo diet's contemporary appeal.
(source: Nielsen Book Data)9783319672496 20180129
Green Library
xvi, 320 pages : illustrations (some color) ; 22 cm.
  • 1. Introduction.- 2. The Status of Patent Medicines.- 3. Constructing the Industry.- 4. Connecting the Country.- 5. Supplying the Consumer.- 6. Persuading the Poorly.- 7. Utilising the Imagination as Therapy.- 8. Harnessing the Potency of Print.- 9. The Legacy of the Patent Medicines Industry.
  • (source: Nielsen Book Data)9783319697772 20180219
In this book, the ownership, distribution and sale of patent medicines across Georgian England are explored for the first time, transforming our understanding of healthcare provision and the use of the printed word in that era. Patent medicines constituted a national industry which was largely popular, reputable and stable, not the visible manifestation of dishonest quackery as described later by doctors and many historians. Much of the distribution, promotion and sale of patent medicines was centrally controlled with directed advertising, specialisation, fixed prices and national procedures, and for the first time we can see the detailed working of a national market for a class of Georgian consumer goods. Furthermore, contemporaries were aware that changes in the consumers' `imagination' increased the benefits of patent medicines above the effects of their pharmaceutical components. As the imagination was altered by the printed word, print can be considered as an essential ingredient of patent medicines. This book will challenge the assumptions of all those interested in the medical, business or print history of the period.
(source: Nielsen Book Data)9783319697772 20180219
SAL3 (off-campus storage)
1 online resource.
  • 1. Introduction: Seriously, What is Precision Medicine? 2. Redefining Disease Causality 3. Genetics: Clues, Not Answers, to the Mysteries of Precision Medicine 4. Disease Convergence 5. The Precision of the Rare Diseases 6. Precision Organisms 7. Reinventing Diagnosis 8. Precision Data 9. Impersonalized Precision Medicine 10. The Alternate Futures of Precision Medicine.
  • (source: Nielsen Book Data)9780128143933 20180312
Despite what you may have read in the popular press and in social media, Precision Medicine is not devoted to finding unique treatments for individuals, based on analyzing their DNA. To the contrary, the goal of Precision Medicine is to find general treatments that are highly effective for large numbers of individuals who fall into precisely diagnosed groups. We now know that every disease develops over time, through a sequence of defined biological steps, and that these steps may differ among individuals, based on genetic and environmental conditions. We are currently developing rational therapies and preventive measures, based on our precise understanding of the steps leading to the clinical expression of diseases. Precision Medicine and the Reinvention of Human Disease explains the scientific breakthroughs that have changed the way that we understand diseases, and reveals how medical scientists are using this new knowledge to launch a medical revolution.
(source: Nielsen Book Data)9780128143933 20180312
1 online resource.
  • 1. Population medicine versus precision medicine 2. Precision Medicine initiatives and programs 3. The role of genomics in personalized medicine 4. Small Data, Big Data, and Data Analytics 5. How Mobile Technology and EHRs can personalize healthcare 6. i2b2, SHRINE, Clinical Query, and Other Research Tools 7. Overcoming the barriers and limitations of precision medicine 8. Interoperability and Personalized Patient Care 9. Protecting patient privacy and implementing security 10. Consumer and Patient Engagement.
  • (source: Nielsen Book Data)9780128116357 20180312
Realizing the Promise of Precision Medicine: The Role of Patient Data, Mobile Technology, and Consumer Engagement explains the potential of personalized medicine and the value of those approaches in making that potential a reality. The book helps transform one-size-fits-all healthcare into a system that focuses on individual needs and the unique needs of each family member, discussing topics such as U.S. sponsored precision medicine initiative, genomics, the role of electronic health records and mobile medicine, patient engagement and empowerment, health information exchange and patient data protection. In addition, the book discusses the barriers and limitations of precision medicine and how to overcome them. Readers will find valuable insights into how big data, patient engagement, mobile technology, and genomics help individualize medical care and offer a pathway to help detect many undiscovered causes of diseases.
(source: Nielsen Book Data)9780128116357 20180312
xv, 240 pages : illustrations ; 24 cm
  • 1. Proprietary medicines and the fiscal state-- 2. The medicine stamp duty and the authority of law-- 3. The tax and the profession of pharmacy-- 4. The tax and the integrity of medicines-- 5. The demise of the tax.
  • (source: Nielsen Book Data)9781107025455 20171127
In 1783, a stamp duty was imposed on proprietary or 'quack' medicines. These largely useless but often dangerous remedies were immensely popular. The tax, which lasted until 1941, was imposed to raise revenue. It failed in its incidental regulatory purpose, had a negative effect in that the stamp was perceived as a guarantee of quality, and had a positive effect in encouraging disclosure of the formula. The book explains the considerable impact the tax had on chemists and druggists - how it led to an improvement in professional status, but undermined it by reinforcing their reputations as traders. The legislation imposing the tax was complex, ambiguous and never reformed. The tax authorities had to administer it, and executive practice came to dominate it. A minor, specialised, low-yield tax is shown to be of real significance in the pharmaceutical context, and of exceptional importance as a model revealing the wider impact of tax law and administration.
(source: Nielsen Book Data)9781107025455 20171127
Green Library
vii, 321 pages : color illustrations ; 28 cm
Medical Library (Lane)
1 online resource : text file, PDF
  • Foreword Chapter 1: Inhaled proteins and peptides. Chapter 2: Inhaled insulin: More compelling than ever. Chapter 3: Inhaled therapeutic siRNA for the treatment of respiratory diseases. Chapter 4: New molecules to treat asthma and COPD. Chapter 5: Inhaled anti-cancer agents. Chapter 6: Inhaled countermeasures for respiratory tract viruses. Chapter 7: Pulmonary delivery of antibiotics for respiratory infections. Chapter 8: Inhaled liposomes. Chapter 9: Inhaled traditional Chinese medicine for respiratory diseases. Chapter 10: Bronchoprovocation tests for evaluation of drug efficacy in asthma.
  • (source: Nielsen Book Data)9781498758048 20171218
The respiratory tract has been used to deliver biologically active chemicals into the human body for centuries. However, the lungs are complex in their anatomy and physiology, which poses challenges to drug delivery. Inhaled formulations are generally more sophisticated than those for oral and parenteral administration. Pulmonary drug development is therefore a highly specialized area because of its many unique issues and challenges. Rapid progress is being made and offers novel solutions to existing treatment problems. Advances in Pulmonary Drug Delivery highlights the latest developments in this field.
(source: Nielsen Book Data)9781498758048 20171218
1 online resource (x, 226 pages) : illustrations.
  • 1. Alcohol a double-edged sword: Health benefits with moderate consumption but a health hazard with excess alcohol intake 2. Drugs of abuse: An overview 3. Designer drugs including bath salts and spices 4. Combined alcohol and drug abuse: A potentially deadly mix 5. Link between environmental factors, personality factors, and addiction 6. Genetic polymorphisms of alcohol metabolizing enzymes associated with protection from or increased risk of alcohol abuse 7. Pharmacogenomics of abused drugs 8. Association between polymorphisms in genes encoding various receptors, transporters, and enzymes and alcohol/drug addiction 9. Methods of alcohol measurement 10. Laboratory methods for measuring drugs of abuse in urine 11. Analysis of drugs of abuse in serum, hair, oral fluid, sweat, and meconium.
  • (source: Nielsen Book Data)9780128054550 20170313
Alcohol, Drugs, Genes and the Clinical Laboratory provides an overview and quick reference to genetic relationships and clinical laboratory information related to the serious public health issue of alcohol and drug abuse. Written in a clear and concise manner, this book discusses the necessary information for health and safety professionals working in public health to learn about complex issues quickly to better help their patients, employees, and others affected by alcohol and drug abuse. Alcohol, Drugs, Genes and the Clinical Laboratory covers the important aspects of drugs and alcohol abuse including genetic aspects along with laboratory methods for analysis of alcohol and abused drugs with emphasis on false positive test results. The book is helpful to healthcare professionals, such as pathologists who oversee alcohol and drug testing, emergency room physicians, family practice physicians who are first healthcare professionals who identify patients susceptible to drug and alcohol abuse, and psychiatrists involved with drug and alcohol rehabilitation programs. It will also be useful to safety professionals who have to assess individuals for workplace responsibilities, ranging from police and recruitment to occupational safety and occupational medicine and public health officials.
(source: Nielsen Book Data)9780128054550 20170313
1 online resource
The definitive guide to the myriad analytical techniques available to scientists involved in biotherapeutics research Analytical Characterization of Biotherapeutics covers all current and emerging analytical tools and techniques used for the characterization of therapeutic proteins and antigen reagents. From basic recombinant antigen and antibody characterization, to complex analyses for increasingly complex molecular designs, the book explores the history of the analysis techniques and offers valuable insights into the most important emerging analytical solutions. In addition, it frames critical questions warranting attention in the design and delivery of a therapeutic protein, exposes analytical challenges that may occur when characterizing these molecules, and presents a number of tested solutions. The first single-volume guide of its kind, Analytical Characterization of Biotherapeutics brings together contributions from scientists at the leading edge of biotherapeutics research and manufacturing. Key topics covered in-depth include the structural characterization of recombinant proteins and antibodies, antibody de novo sequencing, characterization of antibody drug conjugates, characterization of bi-specific or other hybrid molecules, characterization of manufacturing host-cell contaminant proteins, analytical tools for biologics molecular assessment, and more. Each chapter is written by a recognized expert or experts in their field who discuss current and cutting edge approaches to fully characterizing biotherapeutic proteins and antigen reagentsCovers the full range of characterization strategies for large molecule based therapeuticsProvides an up-to-date account of the latest approaches used for large molecule characterizationChapters cover the background needed to understand the challenges at hand, solutions to characterize these large molecules, and a summary of emerging options for analytical characterization Analytical Characterization of Biotherapeutics is an up-to-date resource for analytical scientists, biologists, and mass spectrometrists involved in the analysis of biomolecules, as well as scientists employed in the pharmaceuticals and biotechnology industries. Graduate students in biology and analytical science, and their instructors will find it to be fascinating and instructive supplementary reading.
(source: Nielsen Book Data)9781119053101 20170731
1 online resource (xxi, 570 pages) : illustrations.
  • Anti-Aging Drugs: Where are We and Where are We Going? / Alexander M. Vaiserman and Oleh V. Lushchak
  • Aging: Natural or Disease? A View from Medical Textbooks / S. Janac, B. Clarke and D. Gems
  • The Search for the "Anti-Aging Pill": A Critical Viewpoint / Éric le Bourg
  • Testing of Geroprotectors in Experiments on Cell Cultures: Pros and Cons / Alexander N. Khokhlov and Galina V. Morgunova
  • Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development / Ramón Cacabelos, Juan Carlos Carril and Oscar Teijido
  • Nanotechnology in Anti-Aging: Nutraceutical Delivery and Related Applications / Anila Mathew, Francesco Marotta and D. Sakthi Kumar
  • Hormetins as Drugs for Healthy Aging / Suresh I. S. Rattan
  • Antioxidant Therapy of Aging: From Free Radical Chemistry to Systems Theory of Reliability / V. K. Koltover
  • Mitochondria-Targeted Rechargeable Antioxidants as Potential Anti-Aging Drugs / Elena G. Pasyukova, Boris A. Feniouk and Vladimir P. Skulachev
  • Mimetics of Caloric Restriction / Oleh Lushchak and Dmytro Gospodaryov
  • Allosteric SIRT1 Activators as Putative Anti-Aging Drugs / Basil P. Hubbard
  • Therapeutic Potential of Sirtuin Inhibitors in Cancer / Francisco Javier Alcain, Consuelo M. Nieva, Lucía Fernández del Río, Raquel Santiago-Mora, Elena Gutiérrez-Casado, Mario Duran-Prado and Jose M. Villalba
  • Lifespan-Extending Effect of Resveratrol and Other Phytochemicals / Shin-Hae Lee and Kyung-Jin Min
  • Extending Lifespan by Inhibiting the Mechanistic Target of Rapamycin (mTOR) / Dudley W. Lamming
  • mTOR, Aging and Cancer: Prospects for Pharmacological Interventions / Z. D. Sharp
  • Anti-Aging Action of PPARs: Potential Therapeutic Targets / Ki Wung Chung, Byung Pal Yu and Hae Young Chung
  • Antidiabetic Biguanides as Anti-Aging Drugs / Vladimir N. Anisimov
  • S-Adenosylmethionine Metabolism: A Promising Avenue in Anti-Aging Medicine? / W. A. M. Loenen
  • Melatonin as a Geroprotector: Healthy Aging vs. Extension of Lifespan / R. Hardeland
  • Short Peptides Regulate Gene Expression, Protein Synthesis and Enhance Life Span / Vladimir Khavinson and Irina Popovich
  • HDAC Inhibitors: A New Avenue in Anti-Aging Medicine / E. G. Pasyukova and A. M. Vaiserman
  • Human Life Extension: Opportunities, Challenges, and Implications for Public Health Policy / Ilia Stambler.
Provides an overview of current research aimed to search for life-extending medications and describes pharmacological aspects of anti-aging medicine. Readers are introduced to the historical background of geroprotection in the first chapter. In-depth information on models for investigating geroprotective drugs precedes a section covering anti-aging properties of pharmaceutical compounds, such as calorie restriction mimetics, autophagy inducers, senolytics and mitochondrial antioxidants. Finally, strategies to translate discoveries from aging research into drugs and healthcare policy perspectives on anti-ageing medicine are provided to give a complete picture of the field.
1 online resource (xvii, 456 pages)
  • Preface xvi Abacacavir (Ziagen) 435 Abacavir + Lamivudine + Dolutegravir (Triumeq) 381 Acyclovir (Zovirax) 442 Adefovir (Hepsera) 187 Albendazole (Albenza) 3 Amikacin (Amikin) 9 Amoxicillan 11 Amoxicillin-Clavulanate (Augmentin, Augmentin 600ES, Augmentin XR) 32 Amphotericin B (Fungizone) 169 Amphotericin B Colloidal Dispersion ABCD (Amphotec) 13 Amphotericin B Lipid Complex (Abelcet) 1 Ampicillin 15 Ampicillin-Sulbactam (Unasyn) 394 Anidulafungin (Eraxis) 149 Artemether/Lumefantrine (Coartem) 92 Artesunate 27 Atazanavir (Reyataz) 317 Atazanavir + Cobicistat (Evotaz) 152 Atovaquone (Mepron) 240 Atovaquone/Proguanil (Malarone) 230 Azithromycin (Zithromax, Zmax) 437 Aztreonam (Azactam) 40 Bedaquiline (Sirturo) 337 Benznidazole 51 Bithionol (Bitin) 57 Capreomycin (Capastat) 62 Caspofungin (Cancidas) 60 Cefaclor 66 Cefadroxil (Duricef) 135 Cefamandole (Mandol) 232 Cefazolin (Ancef) 18 Cefdinir (Omnicef) 270 Cefditoren Pivoxil (Spectracef) 343 Cefepime (Maxipime) 234 Cefixime (Suprax) 357 Cefotaxime (Claforan) 87 Cefotetan (Cefotan) 70 Cefoxitin (Mefoxin) 256 Cefpirome (Broact, Cefir, Cefrom, Keiten) 58 Cefpodoxime (Vantin) 406 Ceftaroline fosamil (Teflaro) 365 Ceftazidime (Tazicef, Fortaz ) 165 Ceftazidime and avibactam (Avycaz) 38 Ceftibuten (Cedax) 64 Ceftizoxime (Cefizox) 68 Ceftolozane and Tazobactam (Zerbaxa) 433 Ceftriaxone (Rocephin) 329 Cefuroxime (Zinacef, Ceftin) 72 Cephalexin (Keflex) 212 Chloramphenicol (Chloromycetin) 78 Chloroquine Phosphate (Aralen) 24 Cidofovir (Vistide) 425 Ciprofloxacin (Cipro) 83 Clarithromycin (Biaxin) 52 Clindamycin (Cleocin) 89 Clofazimine (Lamprene) 220 Cobicistat (Tybost) 390 Colistimethate Sodium (Coly-Mycin) 96 Cycloserine (Seromycin) 335 Daclatasvir (Daklinza) 112 Dalbavancin (Dalvance) 114 Dapsone 116 Daptomycin (Cubicin) 107 Darunavir (Prezista) 293 Darunavir + Cobicistat (Prezcobix) 290 Dasabuvir + Ombitasvir + Paritaprevir + Ritonavir (Viekira Pak) 415 Delamanid (Deltyba) 120 Dicloxacillin 124 Diethyl carbamazine/DEC (Hetrazan) 189 Dolutegravir (Tivicay) 375 Doripenem (Doribax) 130 Doxycycline (Vibramycin, Doryx) 132 Efavirenz (Sustiva) 359 Eflornithine (Ornidyl) 274 Elbasvir and Grazoprevir (Zepatier) 431 Elvitegravir (Vitekta) 427 Emtricitabine (Emtriva) 141 Enfuvirtide (Fuzeon) 174 Entecavir (Baraclude) 45 Ertapenem (Invanz) 201 Erythromycin 150 Ethambutol Hydrochloride (Myambutol) 248 Ethionamide (Trecator) 379 Etravirine (Intelence) 196 Famciclovir (Famvir) 157 Fidaxomicin (Dificid) 126 Fluconazole (Diflucan) 127 Flucytosine (Ancobon) 21 Fosamprenavir (Lexiva) 227 Foscarnet (Foscavir) 167 Fosfomycin (Monurol) 246 Ganciclovir Capsules and IV (Cytovene) 106 Gemifloxacin (Factive) 155 Gentamicin (Garamycin) 176 Griseofulvin (Grifulvin V, Grisovulvin, Gris-Peg) 183 Hydroxychloroquine Imipenem-Cilastatin Sodium (Primaxin) 299 Interferon Alpha (Infergen, Intron A) 193 Iodoquinol (Yodoxin) 429 Isavuconazole (Cresemba) 105 Isoniazid 205 Itraconazole (Sporanox) 345 Ivermectin (Stromectol) 353 Kanamycin (Kantrex) 210 Ketoconazole 214 Lamivudine (Epivir) 145 Lamivudine plus Abacavir (Epzicom) 147 Ledipasvir + Sofosbuvir (Harvoni) 185 Levofloxacin (Levaquin) 224 Linezolid (Zyvox) 445 Liposomal Amphotericin B (Ambisome) 7 Lopinavir/Ritonavir (Kaletra) 207 Maraviroc (Selzentry) 333 Mefloquine Hydrochloride (Lariam) 222 Meglumine Antimonite (Glucantime) 182 Melarsoprol B (Mel-B) 238 Meropenem (Merrem) 242 Metronidazole (Flagyl) 159 Micafungin (Mycamine) 250 Miltefosine (Impavido) 191 Minocycline (Minocin, Dynacin) 137 Moxifloxacin (Avelox) 35 Nafcillin 255 Neomycin (Neo-Fradin, Neomycin) 259 Nevirapine (Viramune) 418 Niclosamide (Yomesan) 430 Nifurtimox (Lampit) 219 Nitazoxanide (Alinia) 5 Nitrofurantoin (Furadantin, Macrobid, Macrodantin) 172 Ofloxacin (Floxin) 162 Ombitasvir + Paritaprevir + Ritonavir (Technivie) 363 Oritavancin (Orbactive) 272 Oseltamivir (Tamiflu) 361 Oxacillin 275 Oxamniquine (Vansil) 405 Para-aminosalicylate Sodium (Paser) 277 Peginterferon alpha-2a (Pegasys) 279 Peginterferon alpha-2b (Pegintron) 282 Penicillin (Benzathine Penicillin, Penicillin G, Penicillin V, Procaine Penicillin) 47 Pentamidine (NebuPent, Pentam) 257 Peramivir (Rapivab) 311 Piperacillin (Pipracil) 285 Piperacillin-Tazobactam (Zosyn) 440 Polymixin B Sulfate (Polymixin B) 288 Posaconazole (Noxafil) 264 Praziquantel (Biltricide) 55 Primaquine Phosphate (Primaquine) 298 Pyrantel Pamoate (Antiminth) 23 Pyrazinamide 304 Pyrimethamine (Daraprim) 118 Quinacrine HCl (Atabrine) 28 Quinidine 306 Quinine 308 Raltegravir (Isentress) 203 Ribavirin inhaled (Virazole) 421 Ribavirin oral (Copegus, Rebetol, Ribasphere) 102 Rifabutin (Mycobutin) 252 Rifampin (Rifadin) 320 Rifampin + Isoniazid (Rifamate) 323 Rifampin + Isoniazid + Pyrazinamide (Rifater) 326 Rifapentine (Priftin) 296 Rifaximin (Xifaxan) 427 Rilpivirine (Edurant) 139 Ritonavir (Norvir) 261 Simeprevir (Olysio) 268 Sofosbuvir (Sovaldi) 341 Sofosbuvir + Velpatasvir (Epclusa) 143 Spectinomycin (Trobicin) 387 Spiramycin (Rovamycine) 331 Stibogluconate (Pentostam) 284 Streptomycin 348 Sulfadiazine 355 Suramin Sodium (Germanin) 181 Tedizolid (Sivextro) 339 Telavancin (Vibativ) 413 Telbivudine (Tyzeka) 392 Tenofovir + Emtricitabine + Elvitegravir + Cobicistat (Stribild) 350 Tenofovir + Emtricitabine + Rilpivirine (Complera) 100 Tenofovir Alafenamide + Emtricitabine (Discovy) 122 Tenofovir Alafenamide + Emtricitabine + Elvitegravir + Cobicistat (Genvoya) 178 Tenofovir Alafenamide+ Emtricitabine + Rilpivirine (Odefsey) 266 Tenofovir Alafenamide fumarate (TAF) (Vemlidy) 408 Tenofovir and Emtricitabine (Truvada) 388 Tenofovir Disoproxil Fumarate (Viread) 423 Tenofovir/Emtricitabine/Efavirenz (Atripla) 29 Terbinafine (Lamisil) 217 Tetracycline Hydrochloride 367 Thiabendazole (Mintezole) 244 Ticarcillin-Clavulanate (Timentin) 371 Tigecycline (Tigacyl) 369 Tinidazole (Tindamax) 373 Tobramycin 377 Trimethoprim (Proloprim) 302 Trimethoprim/Sulfamethoxazole (Bactrim, Septra) 42 Valacyclovir (Valtrex) 399 Valganciclovir (Valcyte) 396 Vancomycin-Intravenous 403 Vancomycin-PO (Vancocin) 401 Voriconazole (Vfend) 410 Zanamivir (Relenza) 313 Zidovudine (Retrovir) 315 Zidovudine plus Lamivudine (Combivir) 98 Zidovudine, Lamivudine, and Abacavir (Trizivir) 384 Helpful Formulas, Equations, and Definitions 449 Selected Antimicrobial Toxicities 450 Selected Antimicrobial Coverage 453 Bibliography and References 456.
  • (source: Nielsen Book Data)9781119220756 20171009
A comprehensive compendium of all commonly used antibiotics, including indications, side effects, dosage information, and drug/food interactions Antibiotics Manual: A Guide to Commonly Used Antimicrobials, Second Edition is a unique, user-friendly guide made for all who prescribe antibiotics. It s the only book available that takes a 100% drug-listed approach to 200 of the most common antibiotics prescribed to patients each day. Presented in full color, it s also a convenient reference for every clinician to consult once the decision to use a particular antibiotic has been reached. This edition of Antibiotics Manual includes newer antibiotics that have been released since the publication of the First Edition and updates prescribing information for the older antibiotics. This all-new Second Edition: Has a color-coded interior design which provides quick and easy point of care access for the userIncludes 200 of the most commonly prescribed antibiotics, listed by both brand and generic namesFeatures important recently-released antibiotics such as ceftaroline, tedizolid, and bedaquiline Antibiotics Manual: A Guide to Commonly Used Antimicrobials, Second Edition is a welcome book for physicians in all specialties of medicine who prescribe antibiotics. It is also a handy tool for pharmacists, nurses, nurse practitioners, and physician assistants who want more information on the drugs they administer.
(source: Nielsen Book Data)9781119220756 20171009
xv, 234 pages ; 25 cm.
Green Library
1 online resource (757 pages) : illustrations
  • Introduction to pharmacokinetics and pharmacodynamics
  • Passage of drugs through membranes
  • Drug administration and drug absorption / Steven Sutton
  • Drug distribution
  • Drug elimination and clearance
  • Compartmental models in pharmacokinetics
  • Pharmacokinetics of an intravenous bolus injection in a one-compartment model
  • Pharmacokinetics of an intravenous bolus injection in a two-compartment model
  • Pharmacokinetics of extravascular drug administration / Steven Sutton
  • Introduction to noncompartmental analysis
  • Pharmacokinetics of intravenous infusion in a one-compartment model
  • Multiple intravenous bolus injections in the one-compartment model
  • Multiple intermittent infusions
  • Multiple oral doses
  • Nonlinear pharmacokinetics
  • Introduction to pharmacogenetics
  • Models used to predict drug-drug interactions for orally administered drugs
  • Introduction to physiologically based pharmacokinetic modeling
  • Introduction to pharmacodynamic models and integrated pharmacokinetic--pharmacodynamic models / Diane Mould and Paul Hutson
  • Semi-mechanistic pharmacokinetic--pharmacodynamic model / Diane Mould and Paul Hutson.
Updated with new chapters and topics, this book provides a comprehensive description of all essential topics in contemporary pharmacokinetics and pharmacodynamics. It also features interactive computer simulations for students to experiment and observe PK/PD models in action. Presents the essentials of pharmacokinetics and pharmacodynamics in a clear and progressive manner Helps students better appreciate important concepts and gain a greater understanding of the mechanism of action of drugs by reinforcing practical applications in both the book and the computer modules Features interactive computer simulations, available online through a companion website at: http://www.uri.edu/pharmacy/faculty/rosenbaum/basicmodels.html Adds new chapters on physiologically based pharmacokinetic models, predicting drug-drug interactions, and pharmacogenetics while also strengthening original chapters to better prepare students for more advanced applications Reviews of the 1st edition: This is an ideal textbook for those starting out and also for use as a reference book ." (International Society for the Study of Xenobiotics) and I could recommend Rosenbaum s book for pharmacology students because it is written from a perspective of drug action . . . Overall, this is a well-written introduction to PK/PD . (British Toxicology Society Newsletter).
(source: Nielsen Book Data)9781119143154 20180129
xxv, 434 pages : illustrations ; [ca. 23-29] cm.
  • Bioequivalence & Biopharmaceutical Development Drug Development and Clinical Pharmacology Aims of This Book Biopharmaceutical Development Clinical Pharmacology Statistics in Clinical Pharmacology Structure of the Book History and Regulation of Bioequivalence When and How BE Studies Are Performed Why Are BE Studies Performed? Deciding When Formulations Are Bioequivalent Potential Issues with TOST Bioequivalent Current International Regulation Some Practical Notes Testing for Average Bioequivalence Background Linear Model for 2 x 2 Data Applying the TOST Procedure Carry-over, Sequence, and Interaction Effects Checking Assumptions Made about the Linear Model Power and Sample Size for ABE in the 2 x 2 Design Example Where Test and Reference Are Not ABE Nonparametric Analysis BE Studies with More Than Two Periods Background Three-period Designs Within-subject Variability Robust Analyses for Three Period Designs Four-period Designs Designes with More Than Two Treatments Adjusting for Multiple Testing Nonparametric Analyses of Tmax Technical appendix: Efficiency Tables of Data Special Topics in Bioequivalence Dealing with Special BE Challenges Restricted Maximum Likelihood Modelling Failing BE and the DER Assessment Simulation Data-based Simulation Carry-over Optimal Designs Determining Trial Size What Outliers Are and How to Handle Their Data Bayesian BE Assessment Adaptive Bioequivalence Trials Background Two-stage design for testing for ABE TOST using the standard combination test Example of using the standard combination test The maximum combination test Example of using the maximum combination test Conditional errors and conditional power Algorithm for sample size re-estimation Operating characteristics Conclusions Techniccal Appendix: R code Scaled Average Bioequivalence Testing Background Scaled Average Bioequivalence in Europe Scaled Average Bioequivalence in USA Discussion and Cautions Clinical Pharmacology Clinical Pharmacology Safety Studies Background First-time-in-humans Sub-chronic Dosing Studies Food-Effect Assessment and DDIs Dose-Proportionality Technical Appendix QTc Background Modelling of QTc Data Interpreting the QTc Modelling Findings Design of a Thorough QTc Study in the Future Clinical Pharmacology Efficacy Studies Background Sub-chronic Dosing Phase IIa and the Proof of Concept Population Pharmacokinetics Population and Pharmacokinetics Absolute and Relative Bioavailability Age and Gender Pharmacokinetic Studies Ethnicity Liver Disease Kidney Disease Technical Appendix Vaccines & Epilogue Vaccine Trials Brief Introduction to Vaccine Research and Development Phase I Vaccine Studies Proof of Concept and Phase II Lot Consistency Concomitant Vaccination Cross-over Trials in Vaccines Epilogue Bibliography Index.
  • (source: Nielsen Book Data)9781466585218 20171218
Maintaining a practical perspective, Bioequivalence and Statistics in Clinical Pharmacology, Second Edition explores statistics used in day-to-day clinical pharmacology work. The book is a starting point for those involved in such research and covers the methods needed to design, analyze, and interpret bioequivalence trials; explores when, how, and why these studies are performed as part of drug development; and demonstrates the methods using real world examples. Drawing on knowledge gained directly from working in the pharmaceutical industry, the authors set the stage by describing the general role of statistics. Once the foundation of clinical pharmacology drug development, regulatory applications, and the design and analysis of bioequivalence trials are established, ã including recent regulatory changes in design and analysis and in particular sample-size adaptation, they move on to related topics in clinical pharmacology involving the use of cross-over designs. These include, but are not limited to, safety studies in Phase I, dose-response trials, drug interaction trials, food-effect and combination trials, QTc and other pharmacodynamic equivalence trials, proof-of-concept trials, dose-proportionality trials, and vaccines trials.ã This second edition addresses several recent developments in the field, including new chapters on adaptive bioequivalence studies, scaled average bioequivalence testing, and vaccine trials. Purposefully designed to be instantly applicable, Bioequivalence and Statistics in Clinical Pharmacology, Second Edition provides examples of SAS and R code so that the analyses described can be immediately implemented. The authors have made extensive use of the proc mixed procedures available in SAS.
(source: Nielsen Book Data)9781466585218 20171218
1 online resource : text file, PDF.
  • Analytical characterization. Immunogenicity. Animal studies. Clinical development. Manufacturing, process control. Extrapolation of indications. Interchangeability, substitution. Pharmacovigilance. Statistical issues. Regulatory issues.
  • (source: Nielsen Book Data)9781498718806 20171218
When a biological drug patent expires, alternative biosimilar products are developed. The development of biosimilar products is complicated and involves numerous considerations and steps. The assessment of biosimilarity and interchangeability is also complicated and difficult. Biosimilar Drug Product Development presents current issues for the development of biosimilars and gives detailed reviews of its various stages and contributing factors as well as relevant regulatory pathways and pre- and post-approval issues.
(source: Nielsen Book Data)9781498718806 20171218
1 online resource (342 pages).
With a clear comparative approach, this volume brings together for the first time contributions that cover different periods of the history of ancient pharmacology, from Greek, Byzantine, and Syriac medicine to the Rabbinic-Talmudic medical discourses. This collection opens up new synchronic and diachronic perspectives in the study of the ancient traditions of recipe-books and medical collections. Besides the highly influential Galenic tradition, the contributions will focus on less studied Byzantine and Syriac sources as well as on the Talmudic tradition, which has never been systematically investigated in relation to medicine. This inquiry will highlight the overwhelming mass of information about drugs and remedies, which accumulated over the centuries and was disseminated in a variety of texts belonging to distinct cultural milieus. Through a close analysis of some relevant case studies, this volume will trace some paths of this transmission and transformation of pharmacological knowledge across cultural and linguistic boundaries, by pointing to the variety of disciplines and areas of expertise involved in the process.
(source: Nielsen Book Data)9781501510779 20180129
xxiv, 241 pages : illustrations ; [ca. 23-29] cm.
  • Preface to the Second Edition. Introduction. Organization of a Safety Monitoring Program for a Confirmatory Trial. Meetings. Clinical Issues. Statistical Issues. Biases and Pitfalls. DMC Decisions. Emerging issues. Appendix.
  • (source: Nielsen Book Data)9781498784122 20171218
Praise for the first edition: "Given the author's years of experience as a statistician and as a founder of the first DMC in pharmaceutical industry trials, I highly recommend this book-not only for experts because of its cogent and organized presentation, but more importantly for young investigators who are seeking information about the logistical and philosophical aspects of a DMC." -S. T. Ounpraseuth, The American Statistician ã In the first edition of this well-regarded book, the author provided a groundbreaking and definitive guide to best practices in pharmaceutical industry data monitoring committees (DMCs). Maintaining all the material from the first edition and adding substantial new material, Data and Safety Monitoring Committees in Clinical Trials, Second Edition is ideal for training professionals to serve on their first DMC as well as for experienced clinical and biostatistical DMC members, sponsor and regulatory agency staff. The second edition guides the reader through newly emerging DMC responsibilities brought about by regulations emphasizing risk vs benefit and the emergence of risk-based monitoring. It also provides the reader with many new statistical methods, clinical trial designs and clinical terminology that have emerged since the first edition. The references have been updated and the very popular end-of-chapter Q&A section has been supplemented with many new experiences since the first edition. ã New to the Second Edition: Presents statistical methods, tables, listings and graphs appropriate for safety review, efficacy analysis and risk vs benefit analysis, SPERT and PRISMA initiatives. Newly added interim analysis for efficacy and futility section. DMC responsibilities in SUSARs (Serious Unexpected Serious Adverse Reactions), basket trials, umbrella trials, dynamic treatment strategies /SMART trials, pragmatic trials, biosimilar trials, companion diagnostics, etc. DMC responsibilities for data quality and fraud detection (Fraud Recovery Plan) Use of patient reported outcomes of safety Use of meta analysis and data outside the trial New ideas for training and compensation of DMC members ã Jay Herson is Senior Associate, Biostatistics, Johns Hopkins Bloomberg School of Public Health where he teaches courses on clinical trials and drug development based on his many years experience in clinical trials in academia and the pharmaceutical industry. ã ã ã ã ã ã ã ã ã ã ã ã ã .
(source: Nielsen Book Data)9781498784122 20171218